论文部分内容阅读
研究人员在尼日利亚首都阿布贾指出,对非洲的艾滋病(AIDS)患者而言,科学家研发出新的治疗药物并不一定是他们的福音,因为制药公司根本不会把新药投放到这个世界上最贫穷的大陆。世界卫生组织(WHO)在此间举行的第14届非洲艾滋病与性病国际会议上推荐了艾滋病的最新治疗方案;但其中有些药物在非洲根本不见踪影。无国界医生组织在一份声明中举例指出,美国Abbott公司的新药Kaletra无需冷藏保存,很适合全年气候都很炎热但又经常停电的非洲撒哈拉南部地区,但该公司尚无任何在非洲推广Kaletra的计划;美国Gilead公司研发的药物Tenofovir迄今仅在6个发展中国家有售,尽管该公司两年前就声称要在98个国家以折扣价销售该药。实际上,即使这些药物
Researchers in Abuja, the capital of Nigeria, pointed out that for AIDS patients in Africa, scientists developing new therapeutic drugs are not necessarily their gospel, because pharmaceutical companies will not put new drugs into the world’s poorest Continent. At the 14th International Conference on AIDS and Sexually Transmitted Diseases in Africa, the World Health Organization (WHO) recommended the latest treatment plan for AIDS; however, some of these drugs have not been found in Africa at all. In a statement, Médecins Sans Frontières (MSF) pointed out that Kaletra, the new drug of Abbott Company in the United States, needs not to be kept in cold storage, and is suitable for southern Africa in the sub-Saharan region, where the weather is very hot and frequent, but the company has not yet promoted Kaletra in Africa. The plan; Tenofovir, a drug developed by Gilead of the United States, has so far only been sold in six developing countries, although the company claimed two years ago that it would sell the drug at a discount price in 98 countries. In fact, even these drugs